Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Curent Deferred Tax Liability (2016 - 2019)

Assembly Biosciences has reported Curent Deferred Tax Liability over the past 5 years, most recently at $3.3 million for Q1 2019.

  • Quarterly results put Curent Deferred Tax Liability at $3.3 million for Q1 2019, up 52.26% from a year ago — trailing twelve months through Mar 2019 was $3.3 million (up 52.26% YoY), and the annual figure for FY2018 was $3.3 million, up 52.25%.
  • Curent Deferred Tax Liability for Q1 2019 was $3.3 million at Assembly Biosciences, roughly flat from $3.3 million in the prior quarter.
  • Over the last five years, Curent Deferred Tax Liability for ASMB hit a ceiling of $11.6 million in Q1 2015 and a floor of $2.1 million in Q3 2018.
  • Median Curent Deferred Tax Liability over the past 5 years was $11.1 million (2017), compared with a mean of $8.3 million.
  • Biggest five-year swings in Curent Deferred Tax Liability: plummeted 81.13% in 2018 and later surged 52.26% in 2019.
  • Assembly Biosciences' Curent Deferred Tax Liability stood at $11.6 million in 2015, then decreased by 4.14% to $11.1 million in 2016, then tumbled by 80.79% to $2.1 million in 2017, then skyrocketed by 52.25% to $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019.
  • The last three reported values for Curent Deferred Tax Liability were $3.3 million (Q1 2019), $3.3 million (Q4 2018), and $2.1 million (Q3 2018) per Business Quant data.